Dry Age-Related Macular Degeneration Pharmacology.
Dry Age-Related Macular Degeneration Pharmacology.
复制标题
干性年龄相关性黄斑变性药理学。
DOI：
10.1007/164_2016_36
复制
发表时间：
2017
影响因子：
--
通讯作者：
Ambati,Jayakrishna
中科院分区：
文献类型：
--
作者：
Wright,CharlesB;Ambati,Jayakrishna
Age-related macular degeneration (AMD), the most common form of irreversible blindness in the industrially developed world, can present years before a patient begins to lose vision. For most of these patients, AMD never progresses past its early stages to the advanced forms that are principally responsible for the vast majority of vision loss. Advanced AMD can manifest as either an advanced avascular form known as geographic atrophy (GA) marked by regional retinal pigment epithelium (RPE) cell death or as an advanced form known as neovascular AMD marked by the intrusion of fragile new blood vessels into the normally avascular retina. Physicians have several therapeutic interventions available to combat neovascular AMD, but GA has no approved effective therapies as of yet. In this chapter, we will discuss the current strategies for limiting dry AMD in patients. We will also discuss previous attempts at pharmacological intervention that were tested in a clinical setting and consider reasons why these putative therapeutics did not perform successfully in large-scale trials. Despite the number of unsuccessful past trials, new pharmacological interventions may succeed. These future therapies may aid millions of AMD patients worldwide.
